Staminali cordone ombelicale: il comitato scientifico

Sorgente partecipa attivamente alla ricerca medico-scientifica sulle applicazioni terapeutiche delle cellule staminali. Il nostro Comitato Scientifico annovera tra i suoi Consiglieri e Associati le migliori professionalità italiane e internazionali del mondo della ricerca. Centro nevralgico e cuore pulsante dell’attività di Sorgente, il Comitato è l’occhio vigile della Società sui più recenti sviluppi della medicina rigenerativa e autorizza l’introduzione sul mercato dei prodotti e servizi di Sorgente, a totale garanzia di serietà e qualità per i nostri clienti.

Paolo Fiorina MD PhD - Assistant Professor Harvard Medical School referente Scientifico di Sorgente

Posizioni ricoperte
1993-1997 - Resident Immunology, Parma University, Italy
1997-1999 - Fellow, Medicine, HSR, Milan, Italy
1999-2004 - Attending Physician, HSR, Milan, Italy
2004-2006 - Research Fellow, Harvard Medical School, Boston, MA
2006-2009 - Instructor, Children’s Hospital, Boston, MA
2009 - Assistant Professor, Harvard Medical School, Boston, MA

Associazioni professionali ed altre esperienze
2004-2005 - Member, Grant Commission of the European Community
2005 - Member, ASN (American Society of Nephrology)
2005 - Member, NKF (National Kidney Foundation)
2005 - Member, AST (American Society of Transplantation)
2005 - Member, ESOT (European Society of Transplantation)
2005 - Member, SID (Italian Society of Diabetes)
2009 - Member, ADA (American Diabetes Association)
2009 - Member, JDRF Medical Science Review Committee (MSRC) for Islet Biology and Transplantationx

Onorificenze
2003 - Young Investigator Award of Italian Society of Diabetes, Italian Society of Diabetes
2006 - Young Investigator Award American Society of Transplantation, American Society of Transplantation
2006 - Young Investigator Award American Society of Nephrology, American Society of Nephrology
2007 - AST-JDRF Faculty Grant, American Society of Transplantation
2007 - Young Investigator Award, American Association of Immunology
2008 - Career Development Award, JDRF

Pubblicazioni

1. Fiorina P et al. Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. Lancet. 1996;347(9002):692-3.
2. Fiorina P et al. Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes. 2001;50(3):496-501.
3. Fiorina P et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol. 2003;14(8):2150-8.
4. Fiorina P et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care. 2003;26(4):1129-36.
5. Fiorina P et al. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. Diabetes. 2004;53(9):2291-300.
6. Fiorina P et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005;28(6):1358-65.
7. Fiorina P et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005;28(6):1303-10.
8. Fiorina P et al. Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol. 2006;17(3):716-23.
9. Fiorina P et al. Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes. 2007;56(4):912-20.
10. Fiorina P et al. Altered kidney graft high-energy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care. 2007;30(3):597-603.
11. Fiorina P et al. Metabolic and immunological features of the failing islet transplanted patient. Diabetes Care. 2008 Mar;31(3):436-8. Epub 2007 Dec 10.
12. Abdi R, Fiorina P et al. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008;57(7):1759-67.
13. Fiorina P et al. Targeting CD22 reprograms B cells and reverses autoimmune diabetes. Diabetes. 2008; Nov;57(11):3013-24. Epub 2008 Aug 8.
14. Fiorina P et al. The clinical impact of islet transplantation. Am J Transplant. 2008;8(10):1990-7.
15. Fiorina P et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009 Jul 15;183(2):993-1004. Epub 2009 Jun 26.